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INTRODUCTION 
Epilepsy is as old as mankind.About 3000 years ago, it 
was fully described in Akkadian, the oldest written 
language. It was written in Mesopotamia (now in Iraq). 
Other ancient case histories were found in Egypt from 
1600 B.C., in China from 1700 B.C. and in India from 
1000 B.C.
1The word „epilepsy‟ is derived from the Greek 
Verbεπӷλαμβανεӷν (epilamvanein), meaning “to be seized, 
to be taken hold of, or to be attacked”, epilepsy was 
considered to be the “sacred disease”, and by the 5th 
century B.C. the word had gradually acquired the specific 
and particular meaning associated with it today 
2 
 and 
understanding of epilepsy began with the first known book 
on Epilepsy, “ The Sacred Disease”, by the a number of 
many physician of the Hippocratic School, Hippocrates-the 
Greek Physician, known as “Father of Medicine”.1 But 
modern concept of epilepsy originate in the work of 
physicians and scientists of mid-19
th
 century, the most 
important among them being John Hughlings Jackson 
(1835-1911), the “Father of Neurology”.2Epilepsy is a 
group of neurologic conditions, the common and 
fundamental characteristic of which is recurrent, usually 
unprovoked epileptic seizures, which result from 
excessive, synchronous, abnormal firing of neurons of the 
cerebral cortex.
3
 
Markand,
4
 on long term follow up identifies three 
subgroups of epileptic patients, - (ᵢ)about 60% of the 
patient either remit after a short period or become easily 
controlled by antiepileptic drugs and may eventually remit. 
(ᵢᵢ) 20% of patients develop chronic epilepsy which is 
partially responsive to drugs but the patients continue to 
have scattered recurrent seizures. (ᵢᵢᵢ) The remaining 20% 
have a chronic disorder, unresponsive to conventional 
antiepileptic drugslike Phenytoin, Phenobarbitone, 
Primidone, Ethosuximide, Valproic acid, carbamazepine, 
as monotherapy. And these last two groups i.e. 20%-40% 
are usually treated with polytherapy. 
Duncan et al,
5
, observed that about 80% of patients 
developing seizure disorders will achieve the best control 
with a single drug. For the remainder, add-on another 
therapy provides improved seizure control. And there is 
10%-15% chance of duo therapy controlling seizures when 
monotherapyhas been unsuccessful.
6, 7,  8
 
Add-on therapy is not synonymous with adjunctive therapy 
as adjunctive therapy means measure other than 
antiepileptic drugs or surgical, e.g. education, stress 
management, provision of support for both patient and 
family.
9 
 Add-on therapy is therapy which is added to the 
existing drugs. 
Lamotrigine is an antiepileptic drug of phenyltriazine 
derivative. It acts by inhibiting excess release of excitatory 
neurotransmitter glutamic acid 
10
 and prolonging the 
inactivated state of voltage-gated sodium channel.
11 
 It was 
introduced for add-on treatment for partial seizure in 
Europe in 1991, and in the USA in 1994.
12
 It is used as 
monotherapy in patients with partial and idiopathic 
generalized tonic-clonic epilepsy and offers similar 
efficacy as traditional antiepileptic drugs like phenytoin, 
carbamazepine.
13, 14 
Lamotrigine was used as add-on 
therapy in resistant idiopathic generalized toic-
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clonicepilepsy 
12, 15
 and also resistant partial epilepsy. But 
the previous different studies having varying results.
16, 17
 
In this scenario, there was need of further study especially 
in this area of the country Burdwan Medical College, West 
Bengal, India, where previously no such studies with 
lamotrigine, conducted on the resistant type of primarily 
generalized tonic-clonic epilepsy.   
MATERIALS AND METHODS 
This study was conducted among 46 patients having 
resistant type of primarily generalized tonic-clonic 
epilepsy. Patients were recruited randomly from the out 
patients clinic of the Burdwan Medical College& Hospital 
during the March 2006 to February2007. The study was 
approved by the institutional ethical committee and valid 
written consent was taken from each patients.  
Inclusion criteria: Epileptic patients remaining 
uncontrolled despite the daily use of either valproic acid or 
carbamazepine or combination of valproic acid & 
carbamazepine, at maximally clinically tolerated doses and 
continuing seizure with an average frequency at least one 
seizure per month for the period of at least two years. They 
comprised a group of medically resistant epileptic patients 
according to many scientists.
18, 19, 20,  21 
Patients of both 
sexes were included in my study, ranges of age were 
between 5.3 years to 40.3 years.  
Exclusion criteria:  Pregnant patients, alcoholic patients, 
patients with liver disease, kidney disease, mental disease, 
patients with mesial sclerosis and below 5 years of age, 
were not included in my study. 
Study design: My study was uncontrolled, unblinded and 
open level study for one year and the patients were 
followed up accordingly. 
Statistical analysis:All the collected data were analyzed 
with the descriptive statistics by using the Statistical 
Package for the Social Science (SPSS) ver-16in 
Windows-7. Wilcoxon signed rank test was used for 
comparing the baseline seizure frequency and seizure 
frequency after add-on lamotrigine (p value < 0.05 was 
considered statically significant). But frequency analysis 
was done by manually. 
In my study as patients were taking either valproic acid or 
carbamazepine as monotherapy or combination of valproic 
acid& carbamazepine, so after add-on lamotrigine , there 
were three groups of patients , 1
st
 group – valproic 
acid&lamotrigine, 2
nd
 group – 
carbamazepine&lamotrigine, 3
rd
 group –valproic acid& 
carbamazepine &lamotrigine.Lamotrigine was added as 
3mg/kg body weight in children taking valproic acid and 6 
mg/kg body weight in not taking valproate. In adults it was 
administered as 200 mg-400 mg/day. In both cases doses 
were gradually escalated. After add-on lamotrigine 
efficacy were measured according to efficacy measuring 
scale as % of reduction of seizure frequency from baseline, 
% of patients showed 50% or more reduction of seizure 
frequency and % of patients rendered seizure free.  
RESULTS AND ANALYSIS 
Total numbers of patients recruited in my study were 46 as 
randomly. Among them male were 26 (56.521%) and 
female were 20 (43.478%). Age range was 5.3 years to 
40.3 years, mean age was 17.76 ± 8.09 (mean ± SD). Age 
& sex distribution of the patients are shown in Figure No1 
and in Table No 1: 
Children, adolescents and young adults were the main bulk 
of my study population of patients. 
 
Table No 1:                                    Age and sex distribution of patients 
Age Range                Male              Female                Total 
  No. % No. % No. % 
5 years - 10 years 5 83.33% 1 16.66% 6 13.04% 
11 years - 20 years 10 47.61% 11 52.38% 21 45.65% 
21 years - 30 years 8 50.00% 8 50.00% 16 34.78% 
31 years - 40 years  2 100.00% 0 0% 2 4.35% 
Above 40 years  1 100.00% 0 0% 1 2.17% 
 
Distribution of patients according to age of onset of seizure, are shown in Table No 2 and in Figure No 2.   30.434% of 
my study patients whose age of onset were 5 years or less than 5 years, and 34.78% of patients whose  age of onset of 
seizure were between 11years to 15 years.     
Table No. 2 Distribution of Patients according to the age of onset of seizure 
Age of onset of seizure Male Female Total  % 
≤ 5 years 7 7 14 30.43% 
6 years to 10 years 7 5 12 26.09% 
11 years to 15 years 9 7 16 34.78% 
16 years to 20 years 2 1 3 6.52% 
21 years to 25 years  1 0 1 2.17% 
Total  26 20 46  
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In Figure No. 3 and in Table No. 3 Distribution of patients according to duration of seizure are shown.      
 
Table No. 3 Distribution of Patients According to duration of Seizure 
Duration of Seizure in years Male Female Total % 
≤ 5 years 8 6 14 30.43% 
6 years to 10 years 15 10 25 54.35% 
11 years to 15 years 2 4 6 13.04% 
16 years to 20 years 1 0 1 2.17% 
Total 26 20 46  
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Figure No.1: Showing Age & Sex Distribution of the 
Patients, having Resistant PGTC Epilepsy
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Figure No.2: Showing the Distribution of Patients according to Age of 
Onset of Seizure
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Duration of seizure was calculated as substraction of the 
age of onset of seizure from the present age of the patient. 
Mean duration of seizure was 7.98±3.95 (Mean±SD) 
years. 
Distributions of patients according to different drug 
groups are shown in Table No. 4 and in Figure No. 
4.Before add-on Lamotrigine, the patients either were 
taking Valproic acid or Carbamazepine or the 
combination of these two. After add-on Lamotrigine three 
drug groups produced. Maximum 43.48% of patients 
were belonging to the first group. 
 
Table No. 4 Distribution of Patients according to Different Drug Group 
Drugs  No. of Patients % 
Valproic acid&Lamotrigine 20 43.48% 
Carbamazepine &Lamotrigine 12 26.09% 
Valproic acid &Carbamazepine&Lamotrigine 14 30.43% 
 
 
After add-on Lamotrigine it was seen that 10.869% of patients (5 patients) showed no reduction of seizure frequency from 
the base line value. In the rest of the patients there was reduction of seizure frequency, some showed 100% reduction, ≤ 
50% reduction, ≥50% reduction but < 100% reduction. Details distributions of reduction of seizure frequency after add-on 
Lamotrigine are shown in Table No.5 and in Figure No. 5.  
Table No. 5 Distribution of Patients according to Reduction of Seizure frequency 
% of Reduction of Seizure Frequency No. of Patients % 
0% 5 10.87% 
100% 5 10.87% 
> 0% but < 50% 23 50% 
≥ 50% but < 100% 13 28.26% 
≤ 5 years 6 years to 10 years 11 years to 15 years 16 years to 20 years
% 30.43% 54.35% 13.04% 2.17%
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Figure No. 3: Showing the Distribution of Patients According to 
Duration of Seizure
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Figure No. 4: Showing the Distribution of Patients According to 
different Drug Groups 
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But percentage of reduction of seizure frequency was 
different in the three groups of patients, taking either 
Valproic acid &Lamotrigine, or Carbamazepine 
&Lamotrigine or taking combination of Valproic acid & 
Carbamazepine &Lamotrigine.  
In the first group total patients were 20. Out of that 50% 
responder rate was 45% (9 patients), and15% (3 patients) 
patients rendered seizure free. In the second group total 
patients were 12. Out of that 50% responder rate was 
33.33% (4 patients) and only 8.33% (1 patient) rendered 
seizure free. In the last group total patients were 14. Out of 
that 50% responder rate was 35.71% (5 patients), and only 
7.14% (1 patient) of patient rendered seizure free. The 
details distributions of patients showing % reduction of 
seizure frequency according to three drug groups are 
shown in the Table No. 6 and in Figure No. 6. 
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Figure No. 5: Showing the distribution of Patients according to % 
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Figure No. 6: Showing Distribution of Patients according to % 
Reduction of Seizure Frequency in 3 Different Drug Groups
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Table No.6 Distribution of Patients according to % Reduction of Seizure Frequency in the 
Three Drug Group 
 Drug Groups No. of 
Patient
s  
Reduction of Seizure Frequency as % 
 
  0% 
reduction  
   Above 0% 
but <50% 
  ≥ 50% but 
< 100%    
          
100% 
reduction 
 50% 
Responder 
Rate 
  No % No % No % No % No % 
Valproic acid&Lamotrigine 20 3 15% 8 40% 6 30% 3 15% 9 45% 
Carbamazepine&Lamotrigine 12 1 8.33
% 
7 58.33
% 
3 25% 1 8.33
% 
4 33.33
% 
Valproic 
acid&Carbamazepine&Lamotr
igine 
14 1 7.14
% 
8 57.14
% 
4 28.57
% 
1 7.14
% 
5 35.71
% 
 
But when mean seizure frequency at baseline (per month 
average) calculated before add-on Lamotrigine, it was 
59.39±31.07 (Mean±SD). After add-on Lamotrigine it 
became 31.29 ± 26.19. This was a statistically highly 
significant reduction (p= 0.01). The percentage reduction 
was 47.129%. In this study after add-on Lamotrigine to the 
existing therapy, 10.869% of patients having resistant type 
of Primarily Generalized Tonic-Clonic Epilepsy, rendered 
seizure free and 50% responder rate was 39,129%. 
Responder ratio was -0.32 ± 0.249 (mean ± SD).  
DISCUSSION 
Duncan et.al, 
5
 observed that about 80% of patients 
developing epilepsywill achieve the best control with a 
single drug. For the remainder, combination therapy 
provides improved seizure control but there is 10% - 15% 
chance of duo therapy controlling seizure when 
monotherapyhas been unsuccessful, 
6, 7, 8
.  They also 
reported that about 5% of patients of resistant epilepsy had 
their best possible seizure control on the combination of 
three antiepileptic drugs. 
Ferrendelli
22
,  stated that a substantial number of patients 
with epilepsy perhaps as many as 50% cannot be 
satisfactorily treated with a single drug and two 
antiepileptic drugs and sometimes more may be necessary 
to improve seizure control. In a report of pooled open 
studies involving 667 adult patients with resistant epilepsy, 
the overall efficacy, i.e. 50% responder rate was 32% 
10
, 
Where as in this my study overall 50% responder rate was 
39.129%. Perucca
23
,  on behalf of the study of 105 
investigators, published a pooled result of an open-level 
non blinded multicentricprospective add-on trial of 
Lamotrigine in adult patients with resistant epilepsy and he 
reported that 47% of all patients ( n=338) had a reduction 
in seizure frequency at least 50% compared to baseline. 
All most similar type of study was conducted by Brodie 
et.al 
24
, and they found that overall 50% responder rate was 
47% after add-on Lamotrigine. Matsuo 
12
,  stated that in 
uncontrolled study Lamotrigine had shown efficacy as 
add-on therapy in children and adolescents with resistant 
multiple seizure type with approximately 40% of patients 
showing 50% responder rate and approximately 10% of 
patients rendered seizure free after 3 months of treatment. 
Timmings and Richens 
15
, found that 79% of resistant 
adults with Primarily Generalized Tonic-Clonic Epilepsy 
achieved 50% reduction of seizure frequency. Brodie and 
Yuen 
25
,  found that add-on Lamotrigine caused 50% 
reduction of seizure reduction in 61% of patients with 
resistant primarily generalized tonic-clonic epilepsy.  
Aicardi and Shorovon
26
, stated that high frequencies of 
seizures are predictive of difficulties of control. In this my 
study, patients had also high frequency of seizures. The 
efficacy of an antiepileptic drug lies in its ability to 
interrupt or prevent seizures. In this perspective, the results 
of my study tally with the study of several investigators. 
CONCLUSION 
Add-on Lamotrigine to the existing antiepileptic therapy in 
resistant type of primarily generalized tonic-clonic 
epilepsy was efficaciousat this tertiary care medical 
college hospital, in comparison with other studies in 
different part of the world. 
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